Published in
American Diabetes Association, Diabetes Care, 3(42), p. 494.1-494, 2019
DOI: 10.2337/dc19-er03
Links
Tools
Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042–2050
Journal article published in 2019 by
Lennart Tonneijck,
Mark M. Smits,
Marcel H. A. Muskiet,
Trynke Hoekstra 
,
Mark H. H. Kramer,
A. H. Jan Danser,
Piet M. ter Wee,
Michaela Diamant,
Jaap A. Joles,
Daniel H. van Raalte
,
Mark H. H. Kramer,
A. H. Jan Danser,
Piet M. ter Wee,
Michaela Diamant,
Jaap A. Joles,
Daniel H. van Raalte
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 